[1]傅琪琳,唐颖慧,黄 甫,等.理饮汤治疗肝硬化失代偿期并发肝性胸水疗效研究[J].陕西中医杂志,2019,(6):733-735.
　FU Qilin,TANG Yinghui,HUANG Fu,et al.Effecte of Liyin decoction adjuvant treatment in decompensated cirrhosis with hepatic pleural effusion[J].,2019,(6):733-735.
点击复制

理饮汤治疗肝硬化失代偿期并发肝性胸水疗效研究
分享到：

《陕西中医》杂志[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年6期
页码:
733-735
栏目:
临床研究
出版日期:
2019-06-05

文章信息/Info

Title:
Effecte of Liyin decoction adjuvant treatment in decompensated cirrhosis with hepatic pleural effusion
文章编号:
DOI:10.3969/j.issn.1000-7369.2019.06.014
作者:
傅琪琳; 唐颖慧; 黄 甫; 李粉萍
陕西省中医医院肝病科（西安 710003）
Author(s):
FU Qilin; TANG Yinghui; HUANG Fu; et al.
Shaanxi Hospital of Traditional Chinese Medicine（Xi’an 710003）
关键词:
理饮汤; 肝硬化; 肝功失代偿期; 肝性胸水; 临床疗效; 辨证论治
Keywords:
Key words Liyin decoction; Cirrhosis of liver; Decompensated cirrhosis; Hepatic pleural effusion; Clincal efficacy; Dialectical treatment
分类号:
R256.1
文献标志码:
A
摘要:
摘 要 目的：观察理饮汤联合西药治疗肝硬化失代偿期并发肝性胸水的临床疗效。方法：将100例肝硬化失代偿期并肝性胸水患者随机分成观察组和对照组，各50例，两组患者入院后均给予常规保肝、利尿治疗。观察组在常规治疗基础上予理饮汤口服，7 ｄ为１个疗程，观察３个疗程。评估两组胸水消退情况、治疗前后中医证候评分、肝功及肝性胸水相关并发症的发生情况。结果：与对照组（20.54±11.57）d比较，观察组的胸水消退时间（14.7±8.35）d明显缩短，观察组的总有效率88%要显著优于对照组76%。治疗后两组中医证候评分均显著降低，且观察组（0.85±0.07）分明显低于对照组（1.78±0.06）分。两组患者经治疗肝功ALT、AST均有显著下降，但无统计学意义（ P ＞0.05）。经治疗，观察组肝功ALB（35.23±6.1）g/L有显著上升，且与对照组（31.4±5.25）g/L比较，差异有统计学意义（ P ＜0.05）。观察组胸水相关并发症36%，包括上消化道出血感染、肝肾综合征、肝性脑病、电解质紊乱等的发生率要显著低于对照组50%。结论：西药常规治疗基础上联合理饮汤对肝硬化失代偿期并肝性胸水有良好的治疗作用。
Abstract:
Abstract Objective：To observe the effect of Liyin decoction in treating patients with hepatopleural effusion in decompensated stage of liver cirrhosis.Methods：100 patients with cirrhosis decompensation complicated with hepatic pleural effusion were randomly divided into observation group and control group，50 cases per group.Two groups of patients were given routine liver protection，diuretic treatment after admission.The observation group was treated with Liyin decoction on the basis of routine treatment.7 days was a course of treatment and 3 courses of treatment were observed.To evaluate the regression of hydrothorax，the score of TCM syndromes before and after treatment and the incidence of complications associated with hepatic pleural effusion.Results：Compared with the control group，the hydrothorax regression time in the observation group （14.7±8.35）d was significantly shorter than that in the control group（20.54±11.57）d.The total effective rate of the observation group 88% was significantly better than that of the control group 76%.After treatment，the TCM syndromes scores of the two groups were significantly decreased，and the observation group （0.85±0.07）scores was significantly lower than the control group（1.78±0.06）scores.The ALT and AST of liver function in the two groups decreased significantly after treatment，but there was no significant difference （ P ＞0.05）.After treatment，ALB of liver function in the observation group（35.23±6.1）g/L increased significantly，and compared with the control group（31.4±5.25）g/L，the difference was statistically significant（ P ＜0.05）.The incidence of pleural effusion related complications，including upper gastrointestinal hemorrhage，infection，hepatorenal syndrome，hepatic encephalopathy and electrolyte disorder，was significantly lower in the observation group 36% than in the control group 50%.Conclusion：Combination of Liyin decoction and routine treatment of western medicine has a good effect in decompensated cirrhosis with hepatic pleural effusion，which is worth popularizing in clinic.

参考文献/References:

[1] Gur C,Ilan Y,Shibolet O.Hepatic hydrothorax-pathophysiology diagnosis and treatment-review of the literature[J].Liver Int,2004,24:281-284.
[2]Belcher JM，Garcia-Tsao G，Sanyal AJ, et al .Association of AKI with mortality and complications in hospitalized patients with cirrhosis[J].Hepatology，2013,57:753-762.
[3] 池肇春,叶维法.顽固性腹水诊断标准\[M\].北京:中国医药科技出版社,1994:237.
[4] 国家中医药管理局.中医病证诊断疗效标准\[S\].北京:中国医药科技出版社,2012:1005-1041.
[5] 中国中西医结合学会消化系统疾病专业委员会,肝硬化中西医结合诊疗方案[J].中国中西医结合杂志,2004,24(10):869-871.
[6] 杨 惠,白阳秋,程黎娜.肝性胸水 120 例临床特征回顾性分析[J].医药论坛杂志，2013，34(12):78-79.
[7] 梁士伟.中药茯苓的功能及其应用前景[J].黑龙江医药,2014,27(5):1089-1092.
[8] 张晓娟,左冬冬.白术化学成分及药理作用研究新进展[J].中医药信息,2018,35(6):101-106.
[9] 夏小健,黄 蓓.芍药苷在治疗肝癌中作用及其机制的研究进展[J].中南药学,2018,16(2):209-212.
[10] 梅全喜.现代中医药药理与临床应用手册\[M\].北京:中国中医药出版社,2016:45.

相似文献/References:

[1]田莉婷,刘雪萍,李丹妮,等.加味苓桂术甘汤对脾肾阳虚型肝硬化失代偿期患者生存率的影响*[J].陕西中医杂志,2019,(10):1373.
　TIAN Liting,LIU Xueping,LI Danni,et al.Effect of Jiawei Lingui Shugan decoction on survival rate of patients with spleen，kidney and Yang deficiency type decompensated cirrhosis[J].,2019,(6):1373.
[2]聂姝常,王妙苗,程彬彬.肝硬化合并肠道功能失调的中西医结合治疗研究进展[J].陕西中医杂志,2023,(2):259.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.028]
　NIE Shuchang,WANG Miaomiao,CHENG Binbin.Research progress of traditional Chinese and western medicine for treating intestinal dysfunction in liver cirrhosis[J].,2023,(6):259.[doi:DOI:10.3969/j.issn.1000-7369.2023.02.028]
[3]王子宜,许明岩,王丽媛,等.芪甲软肝丸治疗肝硬化代偿期疗效研究[J].陕西中医杂志,2024,(4):507.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.016]
　WANG Ziyi,XU Mingyan,WANG Liyuan,et al.Effect of Qijia Ruangan pill in the treatment of compensatory stage of liver cirrhosis[J].,2024,(6):507.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.016]

更新日期/Last Update: 2019-06-20